HEMOBLAST Bellows
Dilon Technologies, Inc. · Decision date Apr 28, 2026
What did the FDA approve?
FDA records P170012/S031 as a supplement to PMA P170012, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Apr 28, 2026.
FDA approval order statement
approval for removal of the urological exception from the currently approved indications for use.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Apr 28, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P170012/S031
- Regulatory pathway
- PMA supplement
- Applicant
- Dilon Technologies, Inc.
- Product code
- PMX
- Decision code
- APPR
- Decision date
- Apr 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Absorbable collagen hemostatic agent with thrombin.
- Applicant
- Dilon Technologies, Inc.
- Product code
- PMX
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P170012. Subsequent supplements may change the device or its indications.
FDA decision timeline
P170012 · Original PMA
HEMOBLAST Bellows
P170012/S031 received
Application receipt date recorded by FDA.
P170012/S031 · FDA decision
Normal 180 Day Track
P170012/S032 · Related supplement
HEMOBLAST Bellows
Timeline entries are records held by MedtechLedger for P170012. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170012
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
HEMOBLAST BellowsP170012 | Dilon Technologies, Inc. | PMA approval | Dec 15, 2017 | FDA |
HEMOBLAST BellowsP170012/S032 | Dilon Technologies, Inc. | PMA supplement | Sep 3, 2026 | FDA |
Explore the linked device profile
Other records with product code PMX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Baxter Healthcare Corp | PMA supplement | Nov 13, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Dilon Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 12050 Jefferson Ave., Suite 340, Newport News, VA, 23606
Sources and methodology
- Original FDA record: P170012/S031
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

